MR enterography bests CT enterography, but CT enterography is faster, less expensive, and more widely available.
MR enterography is better than CT enterography for diagnosing fibrosis in pediatric patients with Crohn’s disease, say researchers from Massachusetts General Hospital in Boston.
Researchers, who presented the study this week at the American Roentgen Ray Society Annual Meeting in Vancouver, Canada, evaluated 23 pediatric patients with Crohn’s disease who had both CT enterography and MR enterography examinations to detect fibrosis or inflammation. The results showed that MR enterography was 77.6 percent accurate in depicting fibrosis, compared with 56.9 percent accuracy by CT enterography. The difference was not so significant when looking for active inflammation. MR enterography detected with 82.1 percent accuracy compared with CT enterography accuracy of 77.6 percent.
“While our study shows that MR enterography is as good or better than CT enterography, CT enterography is faster than MR enterography, less expensive, and more widely available,” said Keith Quencer, MD, on of the study authors.
Currently, CT enterography is the preferred imaging modality used to evaluate Crohn’s disease. However, MR enterography does not use radiation.
“Crohn’s disease is a chronic disease, with patients often requiring frequent imaging studies due to symptom recurrence,” said Quencer. “As we strive to minimize radiation dose, particularly in the pediatric population, MR enterography should be considered.”
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.